Aneurysmal Subarachnoid Hemorrhage Trial RandOmizing Heparin
NCT ID: NCT02501434
Last Updated: 2022-03-04
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
SUSPENDED
Clinical Phase
PHASE2
Total Enrollment
88 participants
Study Classification
INTERVENTIONAL
Study Start Date
2016-04-30
Study Completion Date
2024-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A Blind-adjudication Multi-center Phase II Randomized Clinical Trial of Continuous Low-dose Intravenous Heparin Therapy in Coiled Low-grade Aneurysmal Subarachnoid Hemorrhage Patients with Significant Hemorrhage Burden. - STUDY IS TEMPORARILY SUSPENDED WITH PLAN TO RESUME SOON. NO SAFETY CONCERNS
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment of Subarachnoid Hemorrhage With Human Albumin
NCT00283400
Subarachnoid Hemorrhage
TERMINATED
NA
Anticoagulant-associated Intracranial Hemorrhage
NCT06168838
Anticoagulant-induced Bleeding
Intracranial Hemorrhages
RECRUITING
The Role of Statins in Preventing Cerebral Vasospasm Secondary to Subarachnoid Hemorrhage
NCT01346748
Aneurysmal Subarachnoid Hemorrhage
UNKNOWN
PHASE4
Minocycline as Neuroprotectant After Aneurysmal Subarachnoid Hemorrhage
NCT02113176
Subarachnoid Aneurysm Hemorrhage
WITHDRAWN
PHASE1/PHASE2
Tranexamic Acid for Spontaneous Acute Cerebral Hemorrhage Trial
NCT03044184
Stroke Hemorrhagic
Intracerebral Haemorrhage
UNKNOWN
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The primary objective of this study is to investigate the safety and clinical effect of a continuous low-dose intravenous unfractionated heparin (LDIVH) infusion for the prevention of aneurysmal subarachnoid hemorrhage (aSAH) induced neurocognitive dysfunction and other delayed neurological deficits.
Additionally, increased blood and CSF levels of certain inflammatory biomarkers (IL-6, hsCRP, etc) have been correlated to aSAH patients with poor clinical outcomes. Unfractionated heparin (UFH) has known anti-inflammatory actions. As a result, a secondary objective of this study will be to evaluate whether LDIVH can reduce blood and CSF inflammatory biomarkers levels compared to controls and whether there is any association between inflammatory biomarker levels and cognitive outcomes in aSAH.
Additionally, increased blood and CSF levels of certain inflammatory biomarkers (IL-6, hsCRP, etc) have been correlated to aSAH patients with poor clinical outcomes. Unfractionated heparin (UFH) has known anti-inflammatory actions. As a result, a secondary objective of this study will be to evaluate whether LDIVH can reduce blood and CSF inflammatory biomarkers levels compared to controls and whether there is any association between inflammatory biomarker levels and cognitive outcomes in aSAH.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Aneurysmal Subarachnoid Hemorrhage
Neurobehavioral Manifestations
Vasospasm, Intracranial
Intracranial Aneurysm
Heparin-induced Thrombocytopenia Type II
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
SINGLE
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
Standard of Care
Group Type
NO_INTERVENTION
No interventions assigned to this group
LDIVH (Unfractionated Heparin)
Continuous Low-Dose IV Unfractionated Heparin Infusion
Group Type
EXPERIMENTAL
Continuous Low-Dose IV Unfractionated Heparin Infusion
Intervention Type
DRUG
Continuous intravenous infusion of a low-dose unfractionated heparin drip
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Continuous Low-Dose IV Unfractionated Heparin Infusion
Continuous intravenous infusion of a low-dose unfractionated heparin drip
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Heparin
Unfractionated Heparin
Heparin drip
IV Heparin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Age ≥ 18 and ≤ 70 years
2. Historical modified Rankin Scale Score 0-1
3. Aneurysmal subarachnoid hemorrhage caused by a ruptured saccular aneurysm confirmed by catheter angiography that is repaired by endovascular coil embolization. Initiation of the coil embolization procedure should occur within 48 hours from the time of the aneurysm rupture (ictus). In patients where the exact time of the ictus is uncertain, a reasonable estimate of the time of ictus may be assigned. This reasonable time estimate should be considered likely accurate to within hours of the true unknown time.
4. Quality of aneurysm embolization is interpreted to be Raymond-Roy Score of 1 (Complete) or 2 (Residual Neck) indicating that the aneurysm is adequately secured. A tiny amount of contrast in the body of the aneurysm is acceptable as long as the physician considers the aneurysm secured and to NOT represent a Raymond-Roy Score of 3 (Residual Aneurysm).
5. WFNS grade 1 or 2 as assessed after repair of the aneurysm during screening but prior to randomization. A patient who presents with a WFNS greater than 2 who then improves with resuscitation, ventriculostomy, or time is acceptable.
6. The pre-repair, admission head CT demonstrates an aSAH bleed pattern of "thick and diffuse" or "thick and focal" hemorrhage within the subarachnoid basal cisterns measuring ≥ 4 mm in the short axis and ≥ 20 mm in the long axis which is consistent with a modified Fisher grade 3 or 4. Intraventricular hemorrhage is acceptable. Enrollable patients must NOT have a parenchymal hemorrhage greater than 10 cc. Please refer to diagram below for examples. The hemorrhage location should be substantially within the supratentorial space and not isolated to the infratentorial space.
7. The location of the aneurysm should be the anterior circulation, posterior communicating, OR a basilar terminus (apex). Angiographic location of the aneurysm should be confirmed by catheter digital subtraction angiography (DSA) usually obtained during the coil embolization procedure. Patients with PICA or other posterior circulation aneurysms as the cause of the SAH should not be included because they typically cause primarily infratentorial bleed patterns.
8. Ability to screen the patient and obtain a head CT 2-12 hours after the completion of the coiling procedure and the ability to initiate the study drug 12 ± 8 hours after the completion of aneurysm coiling procedure.
9. After recovering from anesthesia following the aneurysm coiling procedure, the patient must remain a WFNS SAH grade ≤ 2 without evidence of a significant new focal neurological deficit including monoparesis / monoplegia, hemiparesis / hemiplegia, or receptive, expressive or global aphasia. New minor cranial nerve defect without any other new findings is permissible. If an NIHSS score was obtained prior to the aneurysm coiling procedure, a post-coiling (pre-enrollment) NIHSS score must not have increased by ≥ 4 points and GCS score must not be decreased by ≥ 2 points. The clinician at the local site should use their best clinical judgment as to whether a significant neurological decline has occurred due to the procedure.
10. Patient is willing and able to return for study follow-up visits.
11. Patient or their Legally Authorized Representative (LAR) has provided written informed consent.
2. Historical modified Rankin Scale Score 0-1
3. Aneurysmal subarachnoid hemorrhage caused by a ruptured saccular aneurysm confirmed by catheter angiography that is repaired by endovascular coil embolization. Initiation of the coil embolization procedure should occur within 48 hours from the time of the aneurysm rupture (ictus). In patients where the exact time of the ictus is uncertain, a reasonable estimate of the time of ictus may be assigned. This reasonable time estimate should be considered likely accurate to within hours of the true unknown time.
4. Quality of aneurysm embolization is interpreted to be Raymond-Roy Score of 1 (Complete) or 2 (Residual Neck) indicating that the aneurysm is adequately secured. A tiny amount of contrast in the body of the aneurysm is acceptable as long as the physician considers the aneurysm secured and to NOT represent a Raymond-Roy Score of 3 (Residual Aneurysm).
5. WFNS grade 1 or 2 as assessed after repair of the aneurysm during screening but prior to randomization. A patient who presents with a WFNS greater than 2 who then improves with resuscitation, ventriculostomy, or time is acceptable.
6. The pre-repair, admission head CT demonstrates an aSAH bleed pattern of "thick and diffuse" or "thick and focal" hemorrhage within the subarachnoid basal cisterns measuring ≥ 4 mm in the short axis and ≥ 20 mm in the long axis which is consistent with a modified Fisher grade 3 or 4. Intraventricular hemorrhage is acceptable. Enrollable patients must NOT have a parenchymal hemorrhage greater than 10 cc. Please refer to diagram below for examples. The hemorrhage location should be substantially within the supratentorial space and not isolated to the infratentorial space.
7. The location of the aneurysm should be the anterior circulation, posterior communicating, OR a basilar terminus (apex). Angiographic location of the aneurysm should be confirmed by catheter digital subtraction angiography (DSA) usually obtained during the coil embolization procedure. Patients with PICA or other posterior circulation aneurysms as the cause of the SAH should not be included because they typically cause primarily infratentorial bleed patterns.
8. Ability to screen the patient and obtain a head CT 2-12 hours after the completion of the coiling procedure and the ability to initiate the study drug 12 ± 8 hours after the completion of aneurysm coiling procedure.
9. After recovering from anesthesia following the aneurysm coiling procedure, the patient must remain a WFNS SAH grade ≤ 2 without evidence of a significant new focal neurological deficit including monoparesis / monoplegia, hemiparesis / hemiplegia, or receptive, expressive or global aphasia. New minor cranial nerve defect without any other new findings is permissible. If an NIHSS score was obtained prior to the aneurysm coiling procedure, a post-coiling (pre-enrollment) NIHSS score must not have increased by ≥ 4 points and GCS score must not be decreased by ≥ 2 points. The clinician at the local site should use their best clinical judgment as to whether a significant neurological decline has occurred due to the procedure.
10. Patient is willing and able to return for study follow-up visits.
11. Patient or their Legally Authorized Representative (LAR) has provided written informed consent.
Exclusion Criteria
1. Angio-negative SAH.
2. History or imaging suggesting that the current hemorrhage presentation is a recent re-rupture of the aneurysm. Prior sentinel headache with negative CT or prior sentinel headache where the patient did not seek medical attention does not exclude the patient.
3. Surgical Clipping (or plan for clipping) of the ruptured aneurysm or any non- ruptured aneurysm on the same admission.
4. Aneurysm is identified to be traumatic, mycotic, blister or fusiform type by catheter DSA.
5. Any intracranial stent placement or non-coil intra-aneurysmal device where dual- antiplatelet therapy is needed during admission.
6. Patient has additional aneurysm(s) that are untreated and could reasonably be considered a possible alternate cause of the aSAH based on the observed bleeding pattern. Adequate treatment of these aneurysms by coiling embolization would result in the aneurysms no longer causing an exclusion. MRI may be used in some situations to determine that the associated aneurysms did not rupture based on lack of blood seen adjacent to the additional aneurysms.
7. Patient received heparin in any form within the last 100 days prior to current presentation / admission.
8. Thrombocytopenia (platelet count less than 100,000 - assuming clumping has been ruled out as a cause).
9. New intraparenchymal hemorrhage or new infarction larger the 15cc in volume, or significant increased mass effect as seen on the post-coiling, pre-enrollment head CT when compared to baseline admission head CT. New hyperdensity on CT scan related to contrast staining is not an exclusion.
10. Patient has a documented history of heparin induced thrombocytopenia (HIT).
11. Patient developed SAH-induced cardiac stunning prior to enrollment, with an ejection fraction \<30%, or requiring IV medications for blood pressure maintenance.
12. Concurrent significant intracranial pathology identified prior to enrollment, including but not limited to, Moyamoya disease, high suspicion or documented CNS vasculitis, severe fibromuscular dysplasia, arteriovenous malformation, arteriovenous fistula, or malignant brain tumor.
13. Thrombolytic therapy within 24 hours prior to enrollment (rtPA, urokinase, etc.)
14. Plan for antiplatelet or oral anticoagulation therapy from the time of the coil embolization procedure until 14 full days after enrollment. Antiplatelet therapy may be resumed after the 14-day window. A single 325 mg Aspirin (or lower dose) given during the coil embolization peri-procedural period is acceptable if this is the local standard of care but should be documented.
15. Concomitant serious or uncontrolled disease such as severe infection, active (non- remission) cancer, severe organ dysfunction (severe heart failure, severe chronic kidney impairment requiring dialysis or severe chronic liver disease) or any coagulopathy (including DIC or bleeding diathesis).
16. Uncontrollable hypertension (\>180 systolic and/or \>110 diastolic) that is not correctable prior to enrollment.
18. Active Immunosuppression therapy including chronic corticosteroid usage.
19. History of gastrointestinal hemorrhage or major systemic hemorrhage within 30 days (including large flank or large retroperitoneal hematoma due to current admission coiling procedure requiring treatment), hemoglobin less than 6 g/dL, INR ≥1.5 after reversal of anticoagulants.
20. Major surgery (including open femoral, aortic, or carotid surgery) within previous 30 days.
21. Currently pregnant.
22. Enrollment in another research study that prescribes a therapeutic treatment that differs from the local standard of care, or that would conflict with this study in some other significant fashion. Registries or coil comparison studies are appropriate.
2. History or imaging suggesting that the current hemorrhage presentation is a recent re-rupture of the aneurysm. Prior sentinel headache with negative CT or prior sentinel headache where the patient did not seek medical attention does not exclude the patient.
3. Surgical Clipping (or plan for clipping) of the ruptured aneurysm or any non- ruptured aneurysm on the same admission.
4. Aneurysm is identified to be traumatic, mycotic, blister or fusiform type by catheter DSA.
5. Any intracranial stent placement or non-coil intra-aneurysmal device where dual- antiplatelet therapy is needed during admission.
6. Patient has additional aneurysm(s) that are untreated and could reasonably be considered a possible alternate cause of the aSAH based on the observed bleeding pattern. Adequate treatment of these aneurysms by coiling embolization would result in the aneurysms no longer causing an exclusion. MRI may be used in some situations to determine that the associated aneurysms did not rupture based on lack of blood seen adjacent to the additional aneurysms.
7. Patient received heparin in any form within the last 100 days prior to current presentation / admission.
8. Thrombocytopenia (platelet count less than 100,000 - assuming clumping has been ruled out as a cause).
9. New intraparenchymal hemorrhage or new infarction larger the 15cc in volume, or significant increased mass effect as seen on the post-coiling, pre-enrollment head CT when compared to baseline admission head CT. New hyperdensity on CT scan related to contrast staining is not an exclusion.
10. Patient has a documented history of heparin induced thrombocytopenia (HIT).
11. Patient developed SAH-induced cardiac stunning prior to enrollment, with an ejection fraction \<30%, or requiring IV medications for blood pressure maintenance.
12. Concurrent significant intracranial pathology identified prior to enrollment, including but not limited to, Moyamoya disease, high suspicion or documented CNS vasculitis, severe fibromuscular dysplasia, arteriovenous malformation, arteriovenous fistula, or malignant brain tumor.
13. Thrombolytic therapy within 24 hours prior to enrollment (rtPA, urokinase, etc.)
14. Plan for antiplatelet or oral anticoagulation therapy from the time of the coil embolization procedure until 14 full days after enrollment. Antiplatelet therapy may be resumed after the 14-day window. A single 325 mg Aspirin (or lower dose) given during the coil embolization peri-procedural period is acceptable if this is the local standard of care but should be documented.
15. Concomitant serious or uncontrolled disease such as severe infection, active (non- remission) cancer, severe organ dysfunction (severe heart failure, severe chronic kidney impairment requiring dialysis or severe chronic liver disease) or any coagulopathy (including DIC or bleeding diathesis).
16. Uncontrollable hypertension (\>180 systolic and/or \>110 diastolic) that is not correctable prior to enrollment.
18. Active Immunosuppression therapy including chronic corticosteroid usage.
19. History of gastrointestinal hemorrhage or major systemic hemorrhage within 30 days (including large flank or large retroperitoneal hematoma due to current admission coiling procedure requiring treatment), hemoglobin less than 6 g/dL, INR ≥1.5 after reversal of anticoagulants.
20. Major surgery (including open femoral, aortic, or carotid surgery) within previous 30 days.
21. Currently pregnant.
22. Enrollment in another research study that prescribes a therapeutic treatment that differs from the local standard of care, or that would conflict with this study in some other significant fashion. Registries or coil comparison studies are appropriate.
Minimum Eligible Age
18 Years
Maximum Eligible Age
70 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Indiana University School of Medicine
OTHER
Sponsor Role
collaborator
Robert F. James
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Robert F. James
Professor of Neurosurgery
Responsibility Role
SPONSOR_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert F James, MD
Role: PRINCIPAL_INVESTIGATOR
Indiana University
J Marc Simard, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Maryland
J Mocco, MD, MSc
Role: PRINCIPAL_INVESTIGATOR
Icahn School of Medicine at Mount Sinai
Kevin N Sheth, MD
Role: PRINCIPAL_INVESTIGATOR
Yale University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yale University
New Haven, Connecticut, United States
Site Status
University of Florida
Gainesville, Florida, United States
Site Status
Tallahassee Neurological Clinic
Tallahassee, Florida, United States
Site Status
Rush University
Chicago, Illinois, United States
Site Status
Indiana University
Indianapolis, Indiana, United States
Site Status
University of Louisville
Louisville, Kentucky, United States
Site Status
University of Michigan
Ann Arbor, Michigan, United States
Site Status
Mount Sinai Ichan School of Medicine
New York, New York, United States
Site Status
University of Texas Southwestern
Dallas, Texas, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Simard JM, Schreibman D, Aldrich EF, Stallmeyer B, Le B, James RF, Beaty N. Unfractionated heparin: multitargeted therapy for delayed neurological deficits induced by subarachnoid hemorrhage. Neurocrit Care. 2010 Dec;13(3):439-49. doi: 10.1007/s12028-010-9435-1.
Reference Type
BACKGROUND
Al-Khindi T, Macdonald RL, Schweizer TA. Cognitive and functional outcome after aneurysmal subarachnoid hemorrhage. Stroke. 2010 Aug;41(8):e519-36. doi: 10.1161/STROKEAHA.110.581975. Epub 2010 Jul 1.
Reference Type
BACKGROUND
Schweizer TA, Al-Khindi T, Macdonald RL. Mini-Mental State Examination versus Montreal Cognitive Assessment: rapid assessment tools for cognitive and functional outcome after aneurysmal subarachnoid hemorrhage. J Neurol Sci. 2012 May 15;316(1-2):137-40. doi: 10.1016/j.jns.2012.01.003. Epub 2012 Jan 26.
Reference Type
BACKGROUND
Wong GK, Lam SW, Ngai K, Wong A, Mok V, Poon WS. Quality of Life after Brain Injury (QOLIBRI) Overall Scale for patients after aneurysmal subarachnoid hemorrhage. J Clin Neurosci. 2014 Jun;21(6):954-6. doi: 10.1016/j.jocn.2013.09.010. Epub 2013 Nov 9.
Reference Type
BACKGROUND
Hong CM, Tosun C, Kurland DB, Gerzanich V, Schreibman D, Simard JM. Biomarkers as outcome predictors in subarachnoid hemorrhage--a systematic review. Biomarkers. 2014 Mar;19(2):95-108. doi: 10.3109/1354750X.2014.881418. Epub 2014 Feb 5.
Reference Type
BACKGROUND
Romero FR, Bertolini Ede F, Figueiredo EG, Teixeira MJ. Serum C-reactive protein levels predict neurological outcome after aneurysmal subarachnoid hemorrhage. Arq Neuropsiquiatr. 2012 Mar;70(3):202-5. doi: 10.1590/s0004-282x2012000300009.
Reference Type
BACKGROUND
Fountas KN, Tasiou A, Kapsalaki EZ, Paterakis KN, Grigorian AA, Lee GP, Robinson JS Jr. Serum and cerebrospinal fluid C-reactive protein levels as predictors of vasospasm in aneurysmal subarachnoid hemorrhage. Clinical article. Neurosurg Focus. 2009 May;26(5):E22. doi: 10.3171/2009.2.FOCUS08311.
Reference Type
BACKGROUND
Tosun C, Kurland DB, Mehta R, Castellani RJ, deJong JL, Kwon MS, Woo SK, Gerzanich V, Simard JM. Inhibition of the Sur1-Trpm4 channel reduces neuroinflammation and cognitive impairment in subarachnoid hemorrhage. Stroke. 2013 Dec;44(12):3522-8. doi: 10.1161/STROKEAHA.113.002904. Epub 2013 Oct 10.
Reference Type
BACKGROUND
Simard JM, Aldrich EF, Schreibman D, James RF, Polifka A, Beaty N. Low-dose intravenous heparin infusion in patients with aneurysmal subarachnoid hemorrhage: a preliminary assessment. J Neurosurg. 2013 Dec;119(6):1611-9. doi: 10.3171/2013.8.JNS1337. Epub 2013 Sep 13.
Reference Type
BACKGROUND
James RF, Shao EY, Page PS, Nazar RG, Martin LB, Dvorak J, Kanaan HK, Daniels MJ, Craycroft J, Rai SN, Everhart DE, Simard JM. Low-dose IV heparin preserves cognitive function in aneurysmal subarachnoid hemorrhage patients. [Unpublished Data]. Presented at AANS 82nd Annual Scientific Meeting. April 5-9, 2014. San Francisco, CA; Abstract #16572.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10550
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Treatment of Subarachnoid Hemorrhage With Human Albumin
NCT01747408
TERMINATED
PHASE1
Subarachnoid Hemorrhage Recovery And Galantamine
NCT02872857
COMPLETED
PHASE1/PHASE2
Intra-Arterial Tenecteplase Following Endovascular Thrombectomy for Large Vessel Occlusion Stroke
NCT06781385
ENROLLING_BY_INVITATION
PHASE2
Use of Simvastatin for the Prevention of Vasospasm in Aneurysmal Subarachnoid Hemorrhage
NCT00487461
TERMINATED
NA
Treatment of Intracerebral Hemorrhage in Patients on Non-vitamin K Antagonist
NCT02866838
COMPLETED
PHASE2/PHASE3
Treating Patients With Aneurysmal SubArachnoid Hemorrhage (SAH) With Epoetin Alfa
NCT00626574
TERMINATED
PHASE4
Safety Study of CN-105 Neuroprotective Peptide for Intracerebral Hemorrhage
NCT02670824
COMPLETED
PHASE1
Evaluation of the Efficacy and Safety of Clazosentan in Reversing Cerebral Vasospasm in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage
NCT02560532
COMPLETED
PHASE2
A Proof of Concept Study to Evaluate CN-105 in ICH Patients
NCT03168581
COMPLETED
PHASE2
A Randomized, Double-Blind, Placebo-Controlled Trial of Simvastatin on Subarachnoid Hemorrhage-Induced Vasospasm
NCT00235963
COMPLETED
PHASE1/PHASE2
Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke
NCT00075959
COMPLETED
PHASE2
Safety and Effect of SANGUINATE™ Infusion in Patients at Risk of Delayed Cerebral Ischemia (DCI) Following Subarachnoid Hemorrhage (SAH)
NCT02323685
COMPLETED
PHASE2
Safety Study of PP-007 in Subjects With Acute Ischemic Stroke
NCT04677777
COMPLETED
PHASE1
Efficacy of Daily IV Administration of Dornase Alfa Up to 14 Days Post Subarachnoid Hemorrhage on Functional Independence At 6 Months
NCT06723717
NOT_YET_RECRUITING
PHASE2
Safety of Intravenous Thrombolytics in Stroke on Awakening
NCT01643902
COMPLETED
PHASE2
Evaluation of CN-105 in Subject With Acute Supratentorial Intracerebral Hemorrhage
NCT03711903
COMPLETED
PHASE2
Addressing Real-world Anticoagulant Management Issues in Stroke
NCT02478177
COMPLETED
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial
NCT03496883
RECRUITING
PHASE3
Satralizumab in Aneurysmal Subarachnoid Hemorrhage
NCT05727657
WITHDRAWN
EARLY_PHASE1
Low-dose Aspirin Therapy in Patients With Ischemic Stroke and Microbleeds
NCT04504864
UNKNOWN
PHASE4
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
NCT03907046
RECRUITING
PHASE3
Study on the Efficacy and Safety of T-02 for the Treatment for Acute Ischemic Stroke
NCT05342038
WITHDRAWN
NA
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2
NCT07227246
RECRUITING
PHASE3
Safety and Feasibility of Using Cerebrolysin in the Treatment of Primary Intracerebral Hemorrhage - a Prospective Randomized Open Blinded End-point Trial
NCT06899464
NOT_YET_RECRUITING
PHASE4
Efficacy and Safety of Minocycline in the Treatment of Intracerebral Hemorrhage
NCT07305896
NOT_YET_RECRUITING
NA